Latest news with #SrishtiGupta
Time of India
a day ago
- Time of India
Tipper used in illegal mining seized in Pkl
Panchkula : Cracking down on illegal mining, police seized a tipper engaged in unlawful extraction in Madhanwala village here Thursday. Special drives are being carried out in the district to curb the practice. DCP Srishti Gupta said strict action will be taken against those involved in illegal mining. She appealed to the public to promptly report any instances of illegal mining to the police or mining department to help safeguard natural resources and uphold law. tnn Stay updated with the latest local news from your city on Times of India (TOI). Check upcoming bank holidays , public holidays , and current gold rates and silver prices in your area. Get the latest lifestyle updates on Times of India, along with Raksha Bandhan wishes , messages and quotes !
Time of India
2 days ago
- Time of India
Panchkula police reunite 415 missing persons with families in a year
Panchkula: Panchkula Police traced and reunited 415 missing individuals with their families over the past year. The police said, this figure, recorded between August 1, 2024, and July 31, 2025, is a testament not only to the vigilance of the police force but also to their deep sense of humanity. DCP Srishti Gupta said among those found were 143 minors under the age of 18. These included 9 boys and 5 girls under 6 years of age, 10 boys and 7 girls between 6 and 12 years, and 18 boys and 94 girls aged between 12 and 18 years. In addition to minors, the police also traced and reunited 207 individuals aged between 18 and 35 — 33 men and 174 women. Another 65 individuals above the age of 35 were located, comprising 38 men and 27 women. Several emotional reunions occurred during the operation, especially in cases where young children or elderly persons were missing. DCP Gupta noted that some of the children were mentally challenged and unable to provide any personal information, such as their name or address. In such cases, police personnel — from station staff to beat officers and ERV (Emergency Response Vehicle) drivers — displayed sensitivity and dedication in handling the situation and achieving success. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Knee pain treatment prices might surprise you Knee pain| search ads Find Now Undo In some cases, children ran away due to domestic conflicts or stress, while others unknowingly boarded trains and reached different states. In such instances, Panchkula Police coordinated with police departments from other states to ensure the safe return of the children to their families. Stay updated with the latest local news from your city on Times of India (TOI). Check upcoming bank holidays , public holidays , and current gold rates and s ilver prices in your area.
Yahoo
01-08-2025
- Business
- Yahoo
Invitation to Idorsia's HY 2025 Financial Reporting webcast and conference call with our new CEO Srishti Gupta
Idorsia will publish its Half Year 2025 Financial Reporting on Wednesday July 30, at 07:00 CEST. An investor webcast and conference call will be held to discuss the results on the same day. Date: Wednesday, July 30, 2025 Time: 14:00 CEST / 13:00 BST / 08:00 EDT The call will start with presentations by senior management, including our new CEO Srishti Gupta, followed by a Q&A session. Live Webcast (audio + slides):The live webcast can be accessed from the Idorsia website Dial-in procedure for analysts (audio only): Analysts who would like to ask questions are required to register in advance of the conference using the following link: Replay: A replay of the investor webcast will be available through approximately 60 minutes after the call has ended. Attachment Press Release PDFError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30-07-2025
- Business
- Yahoo
Strong sales acceleration of QUVIVIQ drives Idorsia toward profitability
Ad hoc announcement pursuant to Art. 53 LR QUVIVIQ™ (daridorexant): Strong performance and sales acceleration with total net sales of CHF 58 million in H1 2025 and increase of 145% compared to the same period in 2024, largely driven by sales in Europe. NDA approval with Simcere in China. Aprocitentan (TRYVIO/JERAYGO) commercial opportunity significantly improved with REMS removal and very positive real-world experience – engaging in partnership discussions. Net revenue H1 2025 of CHF 131 million – boosted by the CHF 32 million exclusivity fee and CHF 40 million milestone from Simcere recognized in H1 2025. US GAAP operating income H1 2025 of CHF 64 million and non-GAAP operating loss of CHF 15 m. Cash runway extended to the end of 2026 – on track to reach commercial profitability goal in 2026 and overall profitability starting from the end of 2027. Allschwil, Switzerland – July 30, 2025Idorsia Ltd (SIX: IDIA) today published its Financial Report for the first half of 2025. The results confirm that the commercial acceleration of QUVIVIQ coupled with the financial discipline implemented over the past 12 months have successfully delivered an operational turn-around. The company is on track to reach its target of overall profitability starting from the end of 2027. Srishti Gupta, MD, Chief Executive Officer of Idorsia, commented: 'The commercial acceleration of QUVIVIQ, combined with our financial discipline, has put Idorsia on track to reach overall profitability starting from the end of 2027. We are advancing the assets in our pipeline that we believe will bring the greatest value to the company and patients. And by using 'lead where we can and partner where we should' as our guiding light, we intend to expand our strategic partnerships, starting with TRYVIO.' Srishti continued:'The removal of the REMS in the US, excellent feedback from early prescribers, and our market preparation work, have significantly improved the commercial opportunity and is making a great basis to engage in the partnership process. Hypertension experts at major centers of excellence confirm positive patient experiences and efficacy and safety consistent with our pivotal clinical trial. This includes the unique ability of TRYVIO to treat hypertensive patients with chronic kidney disease, a condition that is very common in millions of patients with difficult to control hypertension, and who are often underserved with the current guideline directed therapies.' Arno Groenewoud, Chief Financial Officer, commented: 'The excellent performance from QUVIVIQ, particularly in Europe, puts us on-track to reach our improved financial guidance provided in May 2025 and overall profitability starting from the end of 2027. With the newly secured CHF 150 million facility and an updated collaboration with Simcere, bringing an additional CHF 40 million in milestone payments, we have significantly strengthened our financial position and extended our cash runway through the end of 2026. We are currently carefully looking at all options to fund Idorsia to overall profitability starting from the end of 2027.' Commercial operationsIn the first half of 2025, QUVIVIQ™ (daridorexant) in the US, Germany, Italy, Switzerland, Spain, UK, Canada, Austria, France, Sweden, and Finland generated total product sales of CHF 56 million, over 140% increase compared to the same period in 2024. Europe and CanadaQUVIVIQ (daridorexant) net sales in the first half of 2025 reached CHF 44 million in the Europe and Canada (EUCAN) region, an almost 4 times increase from CHF 9 million in the first half of 2024. QUVIVIQ is the only long-term pharmacological treatment for insomnia in Europe and is on-track to become the standard of care. This is reflected by the performance and the extremely positive feedback from both healthcare professionals and patients. The keys to success are to secure public reimbursement, focused promotional efforts to specialist prescribers, and expansion to primary care through co-promotion partnerships and omnichannel initiatives. For more information about QUVIVIQ in the EU, see the Summary of Product Characteristics. For more information about QUVIVIQ in Switzerland, see the Patient Information and Information for Healthcare Professionals. For more information on the marketing authorization of QUVIVIQ in Canada, see the Product Monograph. United StatesQUVIVIQ® (daridorexant) net sales in the first half of 2025 amounted to CHF 11.9 million in the US, compared to CHF 14.2 million in the first half of 2024, with a meaningful improvement in gross margin, driven by greater proportion of payer-paid prescriptions. At the beginning of 2025, the company implemented a streamlined, focused, and more cost-efficient commercialization approach for QUVIVIQ to maintain sales until the potential descheduling of the dual orexin receptor antagonist (DORA) class can be achieved. For more information about QUVIVIQ in the US, see the Full Prescribing Information (PI and Medication Guide). On March 19, 2024, the US Food and Drug Administration (FDA) approved TRYVIO™ (aprocitentan) for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled on other drugs. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. The recommended dosage of TRYVIO is 12.5 mg orally once daily, with or without food. In March 2025, the US FDA fully released TRYVIO from its REMS (Risk Evaluation and Mitigation Strategy) requirement to minimize the burden on the healthcare delivery system of complying with the REMS. As a result, a rapid transition from specialty pharmacy to a wide retail pharmacy distribution model is underway. Funding for a field sales force and promotional activities continues to be dependent on a partnership deal. For more information see the Full Prescribing Information including BOXED Warning (PI and Medication Guide). Research & DevelopmentOur drug discovery engine has produced innovative drugs with the potential to transform the treatment paradigm in multiple therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. The company has completed a portfolio prioritization to advance four investigational clinical assets with the potential to transform treatment paradigms. Lucerastat: Idorsia has conducted a kidney biopsy sub-study belonging to the ongoing open-label extension (OLE) of the Phase 3 study. This sub-study enrolled male participants with classic Fabry disease who had been treated for more than 3 years with lucerastat monotherapy. The main objective of the sub-study was to evaluate the number of globotriaosylceramide (Gb3) inclusions in certain type of kidney cells using established methods of quantification. In parallel, a new interim analysis of the ongoing OLE of the Phase 3 study where ongoing participants had received lucerastat for at least 42 months was performed. The analysis corroborated the long-term effect on plasma Gb3 levels and a potential positive long-term effect on kidney function. It also confirmed the safety and tolerability profile observed during the 6-month randomized treatment period. The results of both the interim analysis and kidney biopsy sub-study are supportive of further investigation for patients with Fabry disease. The company is in ongoing discussions with the US FDA to agree on the optimal regulatory pathway to approval. Daridorexant: Idorsia is conducting a Phase 2 dose-finding study to assess the efficacy, safety, and pharmacokinetics of multiple-dose oral administration of daridorexant in pediatric patients aged 10 to <18 years with insomnia disorder (NCT05423717). The primary objective of the study is to characterize the dose-response relationship of daridorexant on objective total sleep time (TST), using polysomnography. Patients will be randomized in a 1:1:1:1 ratio to 10 mg, 25 mg, or 50 mg daridorexant, or placebo and treated for 2 weeks. The study is expected to complete enrollment by the end of 2025 with readout expected around mid-2026. The study is part of a US FDA-approved Pediatric Study Plan and an EU PDCO-approved Paediatric Investigation Plan. Idorsia will also advance three first-in-class chemokine receptor antagonists into studies which will each be proof-of-concept in the specific indication under investigation as well as proof-of-mechanism for a range of disorders where the pathways can be applied. Key development assets CompoundMechanism of actionTarget indication Status LucerastatGlucosylceramide synthase inhibitorFabry disease New data and evaluation of long-term treatment with lucerastat supportive further investigation – regulatory pathway is under discussion with the FDA DaridorexantDual orexin receptor antagonistPediatric insomnia Phase 2 in pediatric insomnia ongoing with recruitment expected to conclude by end of 2025 with readout expected around mid-2026. IDOR-1117-2520CCR6 receptor antagonistPsoriasis Proof-of-concept study in preparation for patients with psoriasis. Unique potential as a first-in-class, oral, targeted systemic therapy for effective treatment of Th17-driven immuno-dermatology and autoimmune disorders. ACT-1004-1239ACKR3 (CXCR7) receptor antagonistProgressive multiple sclerosis Proof-of-concept study in preparation for patients with progressive MS. Unique combination of re-myelination and anti-inflammatory effect with decreased inflammatory cell infiltration. ACT-777991CXCR3 receptor antagonistVitiligo Proof-of-concept study in preparation for patients with vitiligo. Unique precision medicine with a dual targeting of CD8+ CXCR3+ T cells offers potential for a first-in-class targeted systemic therapy for effective and safer treatment of immuno-dermatology and autoimmune disorders. Further details including the current status of each project in our portfolio can be found in our innovation fact sheet. Vaccine platform: On June 30, 2025, Idorsia announced a milestone in the development of a bacterial vaccine based on the company's synthetic glycan chemistry platform. Initial data from healthy participants showed that the vaccine, which has the potential to be the first-ever directed against Clostridioides difficile (C. difficile) bacteria and spores, is well-tolerated, and induces positive antigen titers in humans that recognize the bacteria. Idorsia will now activate partnering discussions to advance as fast as possible the development of the C. difficile vaccine and the advancement of the technology platform. Financial results US GAAP results First Half Second Quarter in CHF millions, except EPS (CHF) and number of shares (millions) 2025 2024 2025 2024 Net revenue 131 26 72 16 Operating expenses (75) (94) (80) (113) Operating income (loss) 64 (64) (3) (95) Net income (loss) 52 (79) (11) (109) Basic EPS 0.26 (0.44) (0.06) (0.60) Basic weighted average number of shares 195.3 179.5 203.8 179.9 Diluted EPS 0.26 (0.44) (0.06) (0.60) Diluted weighted average number of shares 195.9 179.5 203.8 179.9 Net revenue of CHF 131 million in H1 2025 resulted from QUVIVIQ product sales (CHF 56 million), product sales to partners (CHF 2 million), and contract revenues (CHF 73 million). This compares to net revenue of CHF 26 million in H1 2024 as a result of QUVIVIQ product sales (CHF 23) and contract revenue (CHF 3 million). US GAAP operating expenses of CHF 75 million in H1 2025 and CHF 94 million in H1 2024 were impacted by a one-off gain of CHF 90 million (Viatris deal amendment) in 2025 and CHF 125 million (Viatris deal) in 2024, respectively. Excluding these one-off gains, US GAAP operating expenses at H1 2025 decreased by CHF 54 million, mainly driven by R&D expenses of CHF 50 million decreasing by CHF 21 million compared to H1 2024 (CHF 71 million), and SG&A expenses of CHF 103 million decreasing by CHF 39 million compared to H1 2024 (CHF 142 million). US GAAP net income in H1 2025 amounted to CHF 52 million (CHF 38 million net loss excluding Viatris deal amendment) and CHF 79 million (net loss) in H1 2024 (CHF 204 million net loss excluding Viatris deal). Excluding these one-offs, the reduced net loss in H1 2025 was primarily driven by revenue growth and lower operating expenses resulting from rightsizing efforts initiated at the end of 2024. The US GAAP net income resulted in a basic net income per share of CHF 0.26 (diluted net income per share of CHF 0.26) in H1 2025, compared to a basic net loss per share of CHF 0.44 (diluted net loss per share of CHF 0.44) in H1 2024. Non-GAAP* measures First Half Second Quarter in CHF millions, except EPS (CHF) and number of shares (millions) 2025 2024 2025 2024 Net revenue 130 26 72 16 Operating expenses (152) (200) (75) (104) Operating income (loss) (15) (170) 2 (85) Net income (loss) (25) (183) (1) (96) Basic and diluted EPS (0.13) (1.02) (0.00) (0.54) Basic and diluted weighted average number of shares 195.3 179.5 203.8 179.9 * Idorsia measures, reports, and issues guidance on non-GAAP operating performance. Idorsia believes that these non-GAAP financial measurements more accurately reflect the underlying business performance and therefore provide useful supplementary information to investors. These non-GAAP measures are reported in addition to, not as a substitute for, US GAAP financial performance. Non-GAAP net loss in H1 2025 amounted to CHF 25 million; the difference versus US GAAP net income was mainly driven by the one-off gain from the amendment of the Viatris Deal (CHF 90 million). The non-GAAP net loss resulted in a net loss per share of CHF 0.13 (basic and diluted) in H1 2025, compared to a net loss per share of CHF 1.02 (basic and diluted) in H1 2024. Repurchase OfferOn June 25, 2025, Idorsia announced the launch of the repurchase offer to the holders of its outstanding CHF 200 million convertible bonds maturing in 2025 (CB 2025; ISIN CH0426820350), and CHF 600 million convertible bonds maturing in 2028 (CB 2028; ISIN CH1128004079). The main offer period of the Repurchase Offer started on July 10, 2025, and is expected to end at 17:30 hrs CEST on August 7, 2025. More information can be found in the dedicated press release. New money facilityA new money facility for a net amount of CHF 150 million has been signed and the company drew down the first tranche of CHF 70 million on June 2, 2025. This new money facility has a maturity of 24 months and is fully backstopped by a bondholder group. More information can be found in the dedicated press release. Liquidity and indebtednessAt the end of the first half of 2025, Idorsia's liquidity amounted to CHF 72 million. (in CHF millions) Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Liquidity Cash and cash equivalents 72 51 106 Total liquidity* 72 51 106 Indebtedness Convertible loan 335 335 335 Convertible bond 798 797 797 New money facility 49 - - Other financial debt 189 190 189 Total indebtedness 1,370 1,322 1,321 *rounding differences may occur Liquidity at the end of the first half of 2025 does not include the CHF 40 million milestone recognized in the second quarter from Simcere, following the amendment of the licensing agreement and the approval of QUVIVIQ in China, and the remaining CHF 80 million available under the new money facility. Financial guidance for 2025As previously announced, for the Idorsia-led portfolio in 2025, the company expects a continued acceleration of QUVIVIQ with net sales of around CHF 130 million, COGS of around CHF 15 million, SG&A expenses of around CHF 200 million, and R&D expense of around CHF 90 million, leading to non-GAAP operating expenses of around CHF 305 million. This performance would result in an Idorsia-led business non-GAAP operating loss of around CHF 175 million and US-GAAP operating loss of around CHF 220 million. The company expects US-GAAP EBIT for the partnered business of around CHF 165 million – and mainly driven by the amended deal with Viatris. This would result in a US-GAAP loss for the global business of around CHF 55 million. All amounts exclude unforeseen events and potential revenue related to additional business development activities. Results Day CenterInvestor community: To make your job easier, we provide all relevant documentation via the Results Day Center on our corporate website: Events 9-Month 2025 Financial Results reporting on October 30, 2025 Full-Year 2025 Financial Results reporting on February 26, 2026 Notes to the editor About IdorsiaThe purpose of Idorsia is to challenge accepted medical paradigms, answering the questions that matter most. To achieve this, we will discover, develop, and commercialize transformative medicines – either with in-house capabilities or together with partners – and evolve Idorsia into a leading biopharmaceutical company, with a strong scientific core. Headquartered near Basel, Switzerland – a European biotech hub – Idorsia has a highly experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize the value of our portfolio; a promising in-house development pipeline; and a specialized drug discovery engine focused on small-molecule drugs that can change the treatment paradigm for many patients. Idorsia is listed on the SIX Swiss Exchange (ticker symbol: IDIA). For further information, please contactInvestor & Media RelationsIdorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil+41 58 844 10 10 – – The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as 'intend', "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs, business development activities and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Attachment Press Release PDFError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Time of India
27-07-2025
- General
- Time of India
CET wraps up with display of teamwork, compassion
1 2 Times News Network Panchkula: The Common Eligibility Test (CET)-2025, conducted in four phases on Saturday and Sunday, concluded peacefully in Panchkula. Tight security arrangements were in place for the test, with 525 police personnel deployed to ensure safety. Panchkula DCP Srishti Gupta said that no cases of cheating or irregularities were reported during the two-day examination. She emphasised that robust security arrangements had been made at every centre, and personnel remained fully alert throughout. Special transport support for disabled candidates Haryana government provided free transportation facility for 53 differently-abled candidates in Panchkula district to help them reach their respective exam centres, most of which were located in Chandigarh. Deputy commissioner Monika Gupta informed that candidates were contacted individually and offered the service. All the 53 beneficiaries were picked up from their homes and dropped back after the exam. Parents of the candidates expressed deep gratitude towards the government. Help for injured, pregnant candidates Panchkula SDM Chandrakant Kataria personally transported a woman candidate with a leg injury and a pregnant woman to their exam centres in his official vehicle. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Emergency Generators in Argostoli: (Prices May Surprise You) Emergency Generator | Search Ads Search Now Undo He ensured that they were both also dropped back safely after the exam, reinforcing the administration's commitment to accessibility and compassion. Mass transportation arrangements On the second day of CET-2025, 46 buses were dispatched from Panchkula to transport local candidates to examination centres in Yamunanagar. Simultaneously, 256 buses carrying candidates from Karnal and Kaithal arrived in Panchkula. From six Panchkula locations (Kalka, Pinjore, Morni, Panchkula, Barwala, and Raipur Rani), 25 buses were dispatched for the first shift and 21 for the second shift to Yamunanagar. In return, 80 buses from Karnal and 45 from Kaithal reached Panchkula in the first shift, followed by 81 from Karnal and 50 from Kaithal in the second. Feeder buses were arranged to transport candidates from bus stands to exam centres and back. MSID:: 122936438 413 |
